Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
About Us
Careers
Conferences
Videos
Webinars
Press Releases
Whitepapers
Advertising
Top Story
Financing
Bluebird Bio secures up to $175M in debt financing
Bluebird Bio has secured up to $175 million in debt financing with Hercules Capital, having entered into a five-year term loan facility that provides funds in separate tranches.
Featured
Collaboration
Oxford Nanopore, SeqOne to collaborate on sequencing platform
Artificial Intelligence
Machine-learning model predicts lung and liver cancer through genome sequence changes
Latest News
International consortium launches project to develop next generation of vaccines
March 15, 2024
NGeneBio, Genolution to collaborate on automated NGS system
March 14, 2024
FDA updates draft guidance for Alzheimer's drug development biomarkers
March 14, 2024
Zephyr AI closes $111M series A funding round
March 13, 2024
Business Insights
Financing
Bluebird Bio secures up to $175M in debt financing
Collaboration
Oxford Nanopore, SeqOne to collaborate on sequencing platform
Collaboration
NGeneBio, Genolution to collaborate on automated NGS system
Guideline
FDA updates draft guidance for Alzheimer's drug development biomarkers
Diagnostic Technologies
Artificial Intelligence
Machine-learning model predicts lung and liver cancer through genome sequence changes
Collaboration
NGeneBio, Genolution to collaborate on automated NGS system
Financing
Zephyr AI closes $111M series A funding round
Laboratory Information Systems (LIS)
Metabolon releases integrated bioinformatics platform
Diseases
Artificial Intelligence
Machine-learning model predicts lung and liver cancer through genome sequence changes
Research Consortium
International consortium launches project to develop next generation of vaccines
Guideline
FDA updates draft guidance for Alzheimer's drug development biomarkers
Hereditary Disease
Bluebird Bio signs state Medicaid agreement for SCD gene therapy
More from LabPulse.com
Bluebird Bio signs state Medicaid agreement for SCD gene therapy
By
LabPulse.com staff writers
Bluebird Bio has signed its first outcomes-based Medicaid agreement for its sickle-cell disease (SCD) gene therapy Lyfgenia with the state of Michigan.
March 11, 2024
Metabolon releases integrated bioinformatics platform
By
Matt Limb
Metabolon has launched an integrated bioinformatics platform to aid metabolomics analysis in life sciences research.
March 12, 2024
Harvard team develops compound to combat drug-resistant bacteria
By
Matt Limb
Harvard University researchers say they have created an antibiotic that can overcome many drug-resistant infections.
March 13, 2024
T2 Biosystems granted Nasdaq listing extension
By
LabPulse.com staff writers
Nasdaq's Hearings Panel has granted T2 Biosystems' request for an extension for continued listing on the stock market subject to T2 complying with Nasdaq's rule for market value of listed securities.
March 12, 2024
Predictive AI model might aid early-stage NSCLC planning
By
Liz Carey
The deep-learning AI model identified features that were not readily discernable to a trained pathologist.
March 12, 2024
Patient Square Capital to acquire NanoString assets for $220M
By
LabPulse.com staff writers
NanoString Technologies has reached a binding agreement with Patient Square Capital in which NanoString will sell substantially all of its assets to the investment firm for $220 million.
March 11, 2024
Study: AI assists discovery of prostate cancer subtypes
By
Matt Limb
Prostate tumors have been found to evolve along multiple pathways, leading to two distinct disease types with “pivotal” implications for diagnosis and treatment, say scientists.
March 8, 2024
Ginkgo Bioworks launches technology network
By
Matt Limb
Ginkgo Bioworks has launched a new technology network with 25 partners, pledging to improve customers’ research and development outcomes.
March 6, 2024
MD Anderson Cancer Center acquires cell therapy switch technologies
By
Matt Limb
The University of Texas MD Anderson Cancer Center has acquired inducible switch technologies for development in cell therapy programs from Bellicum Pharmaceuticals.
March 7, 2024
Eisai invests $15M in C2N to increase Alzheimer's test access
By
LabPulse.com staff writers
C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer’s disease tests.
March 6, 2024
Gene-based technique shows potential for rapid diagnostics
By
LabPulse.com staff writers
Biomedical engineers have developed a new gene-based approach which can be used on test strips for rapid, on-the-spot disease detection with accuracy comparable to that of lab-based polymerase chain reaction (PCR) tests.
March 7, 2024
Ibex, PathPresenter ink partnership
By
LabPulse.com staff writers
Ibex Medical Analytics (Ibex) and PathPresenter announced a partnership to enable wider use of AI-enabled digital pathology for their joint customers.
March 6, 2024